AngioDynamics (NASDAQ:ANGO) Releases Earnings Results, Beats Expectations By $0.04 EPS

AngioDynamics (NASDAQ:ANGO) issued its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04, Briefing.com reports. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same quarter last year, the company posted ($0.12) earnings per share. The company’s quarterly revenue was down 14.2% compared to the same quarter last year. AngioDynamics updated its FY25 guidance to ($0.42)-($0.38) EPS and its FY 2025 guidance to -0.420–0.380 EPS.

AngioDynamics Stock Performance

Shares of ANGO traded down $0.27 during mid-day trading on Friday, reaching $6.10. 1,310,782 shares of the company’s stock traded hands, compared to its average volume of 522,570. AngioDynamics has a 12 month low of $5.26 and a 12 month high of $8.25. The stock has a market capitalization of $244.34 million, a P/E ratio of -1.26 and a beta of 0.65. The business’s 50-day moving average price is $7.48 and its 200-day moving average price is $6.62.

Analysts Set New Price Targets

Several research firms recently issued reports on ANGO. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research report on Friday. Canaccord Genuity Group reduced their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.